Role of the bactericidal/permeability-increasing protein in host defence

Current Opinion in Immunology

Volumn 10, Issue 1, 1998, Pages 45-49

  Elsbach, Peter ^a   Weiss, Jerrold ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; OPSONIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HOST RESISTANCE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STRUCTURE; REVIEW;

EID: 0032007337     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80030-7     Document Type: Article

References (48)

1. Broekaert WF, Terras FR, Cammue BP, Osborn RW. Plant defensins: novel antimicrobial peptides as components of the host defense system. Plant Physiol. 108:1995;1353-1358.
2. Hoffmann JA, Reichhart J. Drosophila immunity. of outstanding interest Trends Cell Biol. 7:1997;309-316 An up-to-date review of classical studies of the immune system in Drosophila, revealing close similarities between the regulatory response pathways leading to antimicrobial host defences in an insect and in mammals including humans.
3. Levy O. Antibiotic proteins of polymorphonuclear leukocytes. of special interest Eur J Haem. 56:1996;263-277 A recent comprehensive review of current literature dealing with antimicrobial proteins and peptides of mammalian leukocytes.
4. Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. of special interest Curr Opin Hematol. 4:1997;53-58 Another recent review of a rapidly expanding literature base of antimicrobial proteins and peptides of mammalian leukocytes with a somewhat different focus.
5. Weiss J. Leukocyte-derived antimicrobial proteins. Curr Opin Hematol. 1:1994;78-84.
6. Gazzano-Santoro H, Parent JB, Grinna L, Horwitz A, Parsons T, Theofan G, Elsbach P, Weiss J, Conlon PJ. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun. 60:1992;4754-4761.
7. Elsbach P, Weiss J. Bactericidal/permeability increasing protein and host defense against Gram-negative bacteria and endotoxin. Curr Opin Immunol. 5:1993;103-107.
8. Ooi CE, Weiss J, Levy O, Elsbach P. Isolation of two isoforms of a novel 15-kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. J Biol Chem. 1990;15956-15962.
9. Levy O, Ooi CE, Weiss J, Lehrer RI, Elsbach P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest. 94:1994;672-682.
10. 2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest. 90:1992;1122-1130.
11. Madsen LM, Inada M, Weiss J. Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Infect Immun. 64:1996;2425-2430.
12. Weinrauch Y, Foreman A, Shu C, Zarember K, Levy O, Elsbach P, Weiss J. Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest. 95:1995;1916-1924.
13. Elsbach P, Weiss J, Levy O. Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein. Trends Microbiol. 2:1994;324-328.
14. Ooi CE, Weiss J, Doerfler ME, Elsbach P. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med. 174:1991;649-655.
15. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol. 144:1990;662-666.
16. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol. 148:1992;532-537.
17. Lin Y, Ammons WS, Leach WJ, Kung AH. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock. 2:1994;324-331.
18. Huang K, Conlon PJ, Fishwild DM. A recombinant aminoterminal fragment of bactericidal/permeability-increasing protein (rBPI23) inhibits CD14-mediated LPS-induced endothelial adherence of human neutrophils. Shock. 1:1993;81-86.
19. Betz-Corradin S, Heumann D, Gallay P, Smith J, Mauel J, Glauser MP. Bactericidal/permeability increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide. J Infect Dis. 169:1994;105-111.
20. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem. 262:1987;14891-14894.
21. Lin Y, Kohn FR, Kung AH, Ammons WS. Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia. Biochem Pharmacol. 47:1994;1553-1559.
22. Capodici C, Weiss J. Both N- and C-terminal regions of the bioactive N-terminal fragment of the neutrophil granule bactericidal/permeability-increasing protein are required for stability and function. of special interest J Immunol. 156:1996;4789-4796 This study provides evidence that the antibacterial and endotoxin-neutralizing activities of the amino-terminal 200 residue fragment of bactericidal/permeability-increasing protein do not tolerate much further truncation from either the amino- or the carboxy-terminal end.
23. Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem. 264:1989;9505-9509.
24. Gray PW, Corcorran AE, Eddy RL, Byers MG, Shows TB. The genes for the lipopolysaccharide binding protein (LBP) and the bactericidal/permeability-increasing protein (BPI) are encoded in the same region of chromosome 20. Genomics. 15:1993;188-190.
25. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science. 249:1990;1429-1431.
26. Hubacek JA, Buchler C, Aslanidis C, Schnitz G. The genomic organization of the genes for human lipopolysaccharide binding protein (LBP) and bactericidal/permeability-increasing protein (BPI) is highly conserved. of outstanding interest Biochem Biophys Res Commun. 236:1997;427-430 This important report reveals a nearly identical exon/intron organization of the genes for BPI and LBP that also extends to phospholipid transfer protein and cholesterolester transfer protein, further pointing to the common origin of these proteins.
27. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem. 64:1995;235-257.
28. Dentener MA, Von Asmuth E, Francot GJ, Marra MN, Buurman WA. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol. 151:1993;4258-4265.
29. Gazzano-Santoro H, Meszaros K, Birr C, Carrol SF, Theofan G, Horwitz AH, Lim E, Aberle S, Kasler H, Parent JB. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun. 62:1994;1185-1191.
30. Tobias PS, Soldau K, Iovine N, Elsbach P, Weiss J. Lipopolysaccharide (LPS) binding proteins BPI and LBP form different complexes with LPS. of special interest J Biol Chem. 272:1997;18682-18685 This paper provides the first evidence that the complexes formed between isolated lipopolysaccharide and the genomically and structurally homologous bactericidal/permeability-increasing protein and lipopolysaccharide binding protein are markedly different.
31. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol. 6:1994;125-130.
32. Abrahamson SL, Wu HM, Williams RE, Der K, Ottah N, Little R, Gazzano-Santoro H, Theofan G, Bauer R, Leigh S, et al. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein. Implications in biological activity. of special interest J Biol Chem. 272:1997;2149-2155 The construction and testing of chimeras of bactericidal/permeability-increasing protein (BPI) with lipopolysaccharide binding protein (LBP) further establishes the two-domain structural and functional organization of BPI and LBP and the role of the carboxy-terminal domain of LBP in lipopolysaccharide signaling.
33. Iovine N, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. of outstanding interest Proc Natl Acad Sci USA. 94:1997;10973-10978 This paper establishes for the first time a biological function for the carboxy-terminal half of bactericidal/permeability-increasing protein.
34. Wiese A, Brandenburg K, Lindner B, Schromm AB, Carroll SF, Rietschel ET, Seydel U. Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. of special interest Biochemistry. 36:1997;10301-10310 This study, together with [35], documents for the first time the ability of BPI to insert into negatively charged model lipid membranes, especially with lipopolysaccharides as components.
35. Wiese A, Brandenburg K, Carroll SF, Rietschel ET, Seydel U. Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of Gram-negative bacteria. of special interest Biochemistry. 36:1997;10311-10319 This study, together with [34], documents for the first time the ability of BPI to insert into negatively charged model lipid membranes, especially those containing lipopolysaccharide.
36. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 270:1995;10482-10488.
37. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. of outstanding interest Science. 276:1994;1881-1884 The solving of the three-dimensional structure confirms the two-domain organization of bactericidal/permeability-increasing protein and reveals a highly elongated structure compatible with simultaneous interactions of the amino- and carboxy-terminal domains with lipopolysaccharide-containing particles and host macromolecular acceptors respectively. The resolved structure also provides insights into similar relationships in the other members of the family of lipid (lipopolysaccharide) interactive proteins.
38. Elsbach P, Weiss J. Prospects for the use of recombinant BPI in the treatment of Gram-negative bacterial infections. Infect Agents Dis. 4:1995;102-109.
39. Ammons WS, Kohn FR, Kung AHC. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J Infect Dis. 170:1994;1473-1482.
40. Kung AH, Ammons WS, Lin Y, Kohn FR. Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria. Prog Clin Biol Res. 388:1994;255-263.
41. Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. of special interest Antimicrob Agents Chemother. 40:1996;65-69 This evidence of antimicrobial synergy in vivo of antibiotics and bactericidal/permeability-increasing protein may point to possible clinical application.
42. Reed D: Synergy between endogenous antimicrobials and clinical antibiotics against multi-drug resistant Gram-negative bacteria [PhD thesis]. New York: New York University School of Medicine; 1997.
43. De Winter RJ, Von der Mohlen MA, Van Lieshout H, Wedel N, Nelson B, Friedmann N, Delemarre BJ, van Deventer SJ. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm. 45:1995;193-206.
44. Von der Mohlen MA, Kimmings AN, Wedel NI, Mevissen ML, Jansen J, Friedmann N, Lorenz TJ, Nelson BJ, White ML, Bauer R, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 172:1995;144-151.
45. Von der Mohlen MA, Van Deventer SJ, Levi M, Van den Ende B, Wedel NI, Nelson BJ, Friedmann N, Ten Cate JW. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood. 85:1995;3437-3443.
46. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol. 99:1995;49-56.
47. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM. 89:1996;259-265.
48. Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, Margraf D, Sastry S, Orlowski JP, Bradley JS, et al. Evaluation of rBPI21 (recombinant amino terminal fragment of human bactericidal/permeability-increasing protein) in children with severe meningococcal disease. of special interest Lancet. 350:1997;1439-1443 This report represents the first indication that bactericidal/permeability-increasing protein may protect humans against fulminant Gram-negative bacterial infections.